RLYB (Rallybio Corporation Common Stock) Stock Analysis - News
Rallybio Corporation Common Stock (RLYB) is a publicly traded Healthcare sector company. As of May 21, 2026, RLYB trades at $14.43 with a market cap of $74.70M and a P/E ratio of -5.06. RLYB moved +2.18% today. Year to date, RLYB is +168.41%; over the trailing twelve months it is +427.04%. Its 52-week range spans $1.76 to $15.31. Rallies surfaces RLYB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in RLYB news today?
Rallybio Shareholders to Hold 3.65% Post-Merger as Law Firm Probes Deal Terms: Halper Sadeh LLC is investigating Rallybio Corporation's proposed merger with Candid Therapeutics, which would leave Rallybio shareholders with about 3.65% ownership of the combined company. The firm may seek increased consideration, additional disclosures, or other relief on a contingent fee basis for shareholders.
ADAR1 Capital Management, LLC bought 10.00K (~$139.82K) on May 19, 2026.
ADAR1 Capital Management, LLC bought 200 (~$2.76K) on May 19, 2026.
ADAR1 Capital Management, LLC bought 6.01K (~$83.98K) on May 18, 2026.
RLYB Analyst Consensus
RLYB analyst coverage data. Average price target: $0.00.
Common questions about RLYB
What changed in RLYB news today?
Rallybio Shareholders to Hold 3.65% Post-Merger as Law Firm Probes Deal Terms: Halper Sadeh LLC is investigating Rallybio Corporation's proposed merger with Candid Therapeutics, which would leave Rallybio shareholders with about 3.65% ownership of the combined company. The firm may seek increased consideration, additional disclosures, or other relief on a contingent fee basis for shareholders.
Does Rallies summarize RLYB news?
Yes. Rallies summarizes RLYB news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is RLYB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RLYB. It does not provide personalized investment advice.
